The aim of this study was to assess the alterations in arterial stiffness by calculating CAVI, after therapy with anthracyclines, either with or without anti-HER2 therapy (trastuzumab +/− pertuzumab) in women with breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.